Amneal Pharmaceuticals (AMRX) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Amneal Pharmaceuticals Revenue Highlights


Latest Revenue (Y)

$2.39B

Latest Revenue (Q)

$701.78M

Main Segment (Y)

Generics Segment

Main Geography (Y)

Generics Segment

Amneal Pharmaceuticals Revenue by Period


Amneal Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31$2.39B8.20%
2022-12-31$2.21B5.67%
2021-12-31$2.09B5.08%
2020-12-31$1.99B22.51%
2019-12-31$1.63B-2.20%
2018-12-31$1.66B60.88%
2017-12-31$1.03B1.52%
2016-12-31$1.02B-

Amneal Pharmaceuticals generated $2.39B in revenue during NA 2023, up 8.20% compared to the previous quarter, and up 143.93% compared to the same period a year ago.

Amneal Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-06-30$701.78M6.46%
2024-03-31$659.19M6.84%
2023-12-31$616.98M-0.49%
2023-09-30$620.04M3.50%
2023-06-30$599.05M7.44%
2023-03-31$557.54M-8.56%
2022-12-31$609.76M11.77%
2022-09-30$545.56M-2.47%
2022-06-30$559.36M12.40%
2022-03-31$497.63M-7.31%
2021-12-31$536.90M1.57%
2021-09-30$528.59M-1.21%
2021-06-30$535.08M8.51%
2021-03-31$493.11M-3.32%
2020-12-31$510.03M-1.78%
2020-09-30$519.29M11.76%
2020-06-30$464.66M-6.79%
2020-03-31$498.53M25.47%
2019-12-31$397.33M5.03%
2019-09-30$378.28M-6.51%
2019-06-30$404.64M-9.30%
2019-03-31$446.12M-10.33%
2018-12-31$497.53M4.42%
2018-09-30$476.49M15.15%
2018-06-30$413.79M50.36%
2018-03-31$275.19M-6.20%
2017-12-31$293.37M15.17%
2017-09-30$254.73M-1.98%
2017-06-30$259.87M15.15%
2017-03-31$225.68M-24.41%
2016-12-31$298.58M-

Amneal Pharmaceuticals generated $701.78M in revenue during Q2 2024, up 6.46% compared to the previous quarter, and up 125.87% compared to the same period a year ago.

Amneal Pharmaceuticals Revenue Breakdown


Amneal Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Specialty Segment$390.46M$317.53M---
Generics Segment$1.47B$1.43B$1.37B$1.34B$1.29B
Amneal Specialty Pharma Segment-$374.12M$378.32M$355.57M-
Av K A R E Segment-$406.11M---
Av Kare--$349.01M$293.75M-

Amneal Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Generics Segment (79.03%), and Specialty Segment (20.97%).

Quarterly Revenue by Product

Product/ServiceMar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
Amneal Specialty Pharma Segment$105.23M$96.99M$91.68M$102.55M$89.48M$97.00M$85.09M$101.01M$92.75M$95.93M$85.47M$87.87M$94.26M$97.05M------
Generics Segment$391.29M$753.89M$373.70M$343.81M$399.17M$350.27M$364.89M$317.75M$346.27M$347.13M$360.44M$312.51M$342.14M$341.92M$306.56M$985.00K$300.28M---
Av K A R E Segment--$128.35M$122.06M$108.04M$105.81M$97.46M$94.80M$88.72M$86.00M$84.67M$89.51M$63.85M$57.97M------
Specialty Segment----------$88.64M$87.98M--------
Diclofenac Sodium Gel-----------------$19.26M$25.01M$23.47M
Epinephrine Auto Injector Family Generic Adrenaclick-----------------$22.69M--
Levothyroxine Sodium-----------------$39.77M$46.46M$48.99M
Oxymorphone-----------------$17.14M--
Rytary Family-----------------$33.71M$33.00M$28.83M
Epinephrine Auto-Injector Family (Generic Adrenaclick)------------------$15.96M$15.20M
Yuvafem-Estradiol------------------$14.02M$18.74M

Amneal Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Generics Segment (78.81%), and Amneal Specialty Pharma Segment (21.19%).

Amneal Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20Dec 19
Generics Segment$1.47B$41.09M$35.97M$37.39M$1.29B
Specialty Segment$390.46M$374.12M$378.32M$355.57M$317.53M

Amneal Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: Generics Segment (79.03%), and Specialty Segment (20.97%).

Quarterly Revenue by Country

CountryMar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
Specialty Segment$105.23M$201.78M$96.99M$91.68M$102.55M$89.48M$97.00M$85.09M$101.01M$92.75M$88.64M$95.93M$85.47M$87.87M$94.26M$87.98M----
Generics Segment$391.29M$1.45B$11.14M$12.81M$14.58M$8.72M$12.12M$5.67M$9.09M$8.23M$10.46M$8.18M$9.19M$10.88M$7.24M$985.00K$300.28M$291.02M$335.06M$382.48M

Amneal Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 24: Generics Segment (78.81%), and Specialty Segment (21.19%).

Amneal Pharmaceuticals Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
AMRXAmneal Pharmaceuticals$2.39B$701.78M
NBIXNeurocrine Biosciences$1.89B$622.10M
ALKSAlkermes$1.66B$378.14M
PAHCPhibro Animal Health$977.89M$263.22M
AMPHAmphastar Pharmaceuticals$593.24M$182.39M
COLLCollegium Pharmaceutical$566.77M$144.92M
ANIPANI Pharmaceuticals$486.82M$138.04M
ITCIIntra-Cellular Therapies$462.18M$175.38M
IRWDIronwood Pharmaceuticals$442.74M$94.40M
PROCProcaps Group$409.92M$118.41M
EGRXEagle Pharmaceuticals$316.61M$64.65M
DVAXDynavax$232.28M$73.80M
EOLSEvolus$199.72M$66.22M
DCPHDeciphera Pharmaceuticals$163.36M$45.00M
ASRTAssertio$152.07M$31.13M
LFCRLifecore Biomedical$128.26M$24.70M
AGRXAgile Therapeutics$19.59M$5.58M
SSICSilver Spike Investment$11.72M$2.76B
ACRXTalphera$651.00K$117.00K

AMRX Revenue FAQ


Amneal Pharmaceuticals's yearly revenue for 2023 was $2.39B, representing an increase of 8.20% compared to 2022. The company's yearly revenue for 2022 was $2.21B, representing an increase of 5.67% compared to 2021. AMRX's yearly revenue for 2021 was $2.09B, representing an increase of 5.08% compared to 2020.

Amneal Pharmaceuticals's quarterly revenue for Q2 2024 was $701.78M, a 6.46% increase from the previous quarter (Q1 2024), and a 17.15% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $659.19M, a 6.84% increase from the previous quarter (Q4 2023), and a 18.23% increase year-over-year (Q1 2023). AMRX's quarterly revenue for Q4 2023 was $616.98M, a -0.49% decrease from the previous quarter (Q3 2023), and a 1.18% increase year-over-year (Q4 2022).

Amneal Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 14.33%, and for the last 5 years (2019-2023) was 47.17%.

Amneal Pharmaceuticals's revenue streams in c 23 are Specialty Segment, and Generics Segment. Specialty Segment generated $390.46M in revenue, accounting 20.97% of the company's total revenue, up 22.97% year-over-year. Generics Segment generated $1.47B in revenue, accounting 79.03% of the company's total revenue, up 2.75% year-over-year.

For the fiscal year ending Dec 23, the largest source of revenue of Amneal Pharmaceuticals was Generics Segment. This segment made a revenue of $1.47B, representing 79.03% of the company's total revenue.